Evommune: Robust IL-18 Phase 2a Atopic Dermatitis Data Underpins Buy Rating and Higher $55 Target with Additional Indication Upside

Evercore ISI analyst Gavin Clark-Gartner has maintained their bullish stance on EVMN stock, giving a Buy rating today.

Gavin Clark-Gartner has given his Buy rating due to a combination of factors, primarily the strength of Evommune’s IL-18 Phase 2a atopic dermatitis data, which showed a meaningful improvement in disease severity and responder rates versus placebo at 12 weeks. He increases the probability of success for this program to 50% and lifts his price target to $55 per share, arguing that the IL-18 asset on its own can justify the company’s valuation with additional upside.

Gavin Clark-Gartner’s rating is based on his view that the efficacy signals appear robust, the safety profile is clean, and key concerns about data quality or patient mix are either limited in magnitude or readily addressable. He also notes that his valuation does not yet capture potential expansion of IL-18 into other inflammatory indications such as inflammatory bowel disease, which he sees as a future value driver beyond the current atopic dermatitis opportunity.